News

Irish Star on MSN26m
One common habit at night could be early red flag for stroke or heart failure
The research, conducted by sleep specialists at Flinders University, found that individuals, especially overweight ...
Investor's Business Daily on MSN33m
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions ...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...